BLRX BioLineRx Ltd.
BioLineRx Ltd. (BLRX) is expected to report earnings on August 13, 2026, before the market open. The consensus earnings estimate is $0.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.9% since its last earnings release on May 27, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BioLineRx Ltd.
Bioline Rx Ltd is a clinical stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds in areas of central nervous system, oncology, cardiovascular, & infectious diseases, among others.
Sector
Healthcare
Industry
Drug Manufacturers/Other